Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MaxCyteMXCT -5.38%67 3-Year Share Buyback Ratio is -1.40 as of Jun. 2026. GuruFocus rates MXCT with a GF Score™ of 67/100 and a GF Value™ of $2.28 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 612 Medical Devices & Instruments companies, MaxCyte ranks better than 57.68% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. MaxCyte's current 3-Year Share Buyback Ratio was -1.40%.
The historical rank and industry rank for MaxCyte's 3-Year Share Buyback Ratio or its related term are showing as below:
MXCT'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -25.4 Med: -5.4 Max: 0
Current: -1.4
During the past 13 years, MaxCyte's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -25.40%. And the median was -5.40%.
MXCT's 3-Year Share Buyback Ratio is ranked better than 57.68% of 612
companies
in the Medical Devices & Instruments industry
Industry Median: -2.6
vs MXCT: -1.40
MaxCyte (NAS:MXCT) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
MaxCyte 3-Year Share Buyback Ratio Related Terms
MXCT vs STIM, CVRX, RPID: 3-Year Share Buyback Ratio Comparison
For the Medical Devices subindustry, MaxCyte's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where MaxCyte's 3-Year Share Buyback Ratio falls into.
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -1.40 mean?
MaxCyte (MXCT) has a 3-Year Share Buyback Ratio of -1.40 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for MaxCyte and its competitors. According to the industry distribution chart, MaxCyte ranks #259 out of 612 companies in the Medical Devices & Instruments industry, placing it in the top 42.3%.
Is MaxCyte's 3-Year Share Buyback Ratio too high?
MaxCyte's current 3-Year Share Buyback Ratio is -1.40. Based on the distribution chart, MaxCyte ranks #259 out of 612 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MaxCyte has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's 3-Year Share Buyback Ratio compare to STIM and CVRX?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #259 out of 612 companies for 3-Year Share Buyback Ratio. This puts MaxCyte in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for MaxCyte and its competitors. MaxCyte's current 3-Year Share Buyback Ratio is -1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.28, compared to a current price of $1.33 — trading 41.9% below its estimated fair value. The current 3-Year Share Buyback Ratio is -1.40. MaxCyte's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For MaxCyte (MXCT), the current 3-Year Share Buyback Ratio is -1.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.33 is trading 41.9% below its estimated GF Value™ of $2.28.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
3-Year Share Buyback Ratio: -1.40
GF Value™: $2.28 vs. price of $1.33 (41.9% below fair value)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
67GF Score
Get the complete analysis for MXCT
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
